Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

前日（2月7日）， 全球骨科手术机器人龙头企业Globus Medical（NYSE: GMED）宣布以每股5.85美元的价格收购慢性疼痛治疗公司Nevro（NYSE: NVRO）全部股份，总股权价值达2.5亿美元（约合18.2亿元人民币） 。这一价格较Nevro过去90天的平均股价溢价27%，较30天平均股价溢价38%，交易预计于2025年第二季度末完成。

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

周五，Piper Sandler分析师Adam Maeder将市值2.14亿美元的医疗设备公司Nevro Corp (NYSE: NVRO )的股票评级从减持上调至中性，并将目标价从6.00美元下调至5.85美元。此次调整是在Nevro宣布与Globus Medical Inc. (NYSE: GMED )达成最终收购协议后做出的，后者将以每股5.85美元的现金价格收购Nevro。

周四，Canaccord Genuity维持Globus Medical (NYSE: GMED )的买入评级，目标价为101.00美元。该公司目前股价为88.54美元。该机构的分析支持公司当前战略，特别是在收购Nevro Corp之后。Canaccord Genuity对Globus ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...

Spinal Cord Stimulators Market. The global spinal cord stimulators market is on an accelerated growth path, projected to ...